Introduction Ketamine, an NMDA receptor antagonist, has shown promise in the treatment of various psychiatric disorders, including depression and PTSD. Its rapid-acting therapeutic effects have made it an appealing option in clinical settings under strict supervision. However, the trend towards take-home ketamine, facilitated through prescriptions for nasal sprays and oral lozenges, raises significant safety and efficacy concerns. This blog entry explores some of the reasons
